Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating lorlatinib and crizotinib for refractory ALK-rearranged advanced non-small cell lung cancer
ACTRN12619000844145Phase 2Completed
- Sponsor
- Royal North Shore Hospital
- Start
- Jun 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorlatinib and crizotinib in non-small cell lung cancer (NSCLC) and ALK-positive non-small cell lung cancer, sponsored by Royal North Shore Hospital. Primary endpoint: Time to treatment failure with alternating ALK inhibitor therapy. Started Jun 2019; status: completed.
02
Drugs
lorlatinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on ACTRN12619000844145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000844145.